Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs

[1]  Andreas M. Abend,et al.  Current Approaches for Dissolution Similarity Assessment, Requirements, and Global Expectations , 2022, The AAPS Journal.

[2]  John P. Rose,et al.  An IQ Consortium Perspective on Connecting Dissolution Methods to In Vivo Performance: Analysis of an Industrial Database and Case Studies to Propose a Workflow , 2022, The AAPS Journal.

[3]  S. Kollipara,et al.  Applications of PBPK/PBBM modeling in generic product development: An industry perspective , 2022, Journal of Drug Delivery Science and Technology.

[4]  N. Patel,et al.  Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling , 2022, The AAPS journal.

[5]  S. Kollipara,et al.  Simplified Model-Dependent and Model-Independent Approaches for Dissolution Profile Comparison for Oral Products: Regulatory Perspective for Generic Product Development , 2022, AAPS PharmSciTech.

[6]  T. Heimbach,et al.  Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-Space for Ribociclib which has Permeation Rate-Controlled Absorption. , 2021, Journal of pharmaceutical sciences.

[7]  Lawrence X. Yu,et al.  Understanding In Vivo Dissolution of Immediate Release (IR) Solid Oral Drug Products Containing Weak Acid BCS Class 2 (BCS Class 2a) Drugs , 2021, The AAPS Journal.

[8]  F. Bois,et al.  A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms , 2021, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  T. Heimbach,et al.  Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms Using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies. , 2021, Journal of pharmaceutical sciences.

[10]  M. Jamei,et al.  Mechanistic PBPK Modelling to Predict the Advantage of the Salt Form of a Drug When Dosed with Acid Reducing Agents , 2021, Pharmaceutics.

[11]  S. Peters,et al.  Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol , 2021, CPT: pharmacometrics & systems pharmacology.

[12]  S. Jaiswal,et al.  Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets , 2021, Drug development and industrial pharmacy.

[13]  Paul Seo,et al.  Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs , 2021, The AAPS Journal.

[14]  Anshul Gupta,et al.  Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research , 2020, The AAPS Journal.

[15]  Zhou Zhou,et al.  In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  J. Dressman,et al.  The use of PBPK/PD to establish clinically relevant dissolution specifications for zolpidem immediate release tablets. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  Liang Zhao,et al.  Using a Physiologically Based Pharmacokinetic Absorption Model to Establish Dissolution Bioequivalence Safe Space for Oseltamivir in Adult and Pediatric Populations , 2020, The AAPS Journal.

[18]  Lei Zhang,et al.  Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs , 2020, CPT: pharmacometrics & systems pharmacology.

[19]  J. Dressman,et al.  Suitability of the z-Factor for Dissolution Simulation of Solid Oral Dosage Forms: Potential Pitfalls and Refinements. , 2020, Journal of pharmaceutical sciences.

[20]  Takafumi Kato,et al.  Establishment of a clinically relevant specification for dissolution testing using physiologically based pharmacokinetic (PBPK) modeling approaches. , 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  Boštjan Petek,et al.  In vitro–In vivo Relationship and Bioequivalence Prediction for Modified-Release Capsules Based on a PBPK Absorption Model , 2019, AAPS PharmSciTech.

[22]  Sarfaraz K Niazi.  Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs—General Considerations , 2019 .

[23]  Rodrigo Cristofoletti,et al.  Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. Case example: Naproxen. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Hao Zhu,et al.  Consideration of a Credibility Assessment Framework in Model‐Informed Drug Development: Potential Application to Physiologically‐Based Pharmacokinetic Modeling and Simulation , 2019, CPT: pharmacometrics & systems pharmacology.

[25]  Yingli Wang,et al.  Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products based on PBPK Modeling: An In-depth Analysis. , 2019, Molecular pharmaceutics.

[26]  Alexander Blanazs,et al.  Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  Anette Müllertz,et al.  In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[28]  R. Löbenberg,et al.  The Irrelevance of In Vitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping. , 2019, Journal of pharmaceutical sciences.

[29]  Malcolm Rowland,et al.  Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective , 2018, Clinical pharmacology and therapeutics.

[30]  C. Germa,et al.  Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations , 2017, Clinical pharmacology and therapeutics.

[31]  Patrick Augustijns,et al.  Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study. , 2017, Molecular pharmaceutics.

[32]  R. Lionberger,et al.  Integrating In Vitro, Modeling, and In Vivo Approaches to Investigate Warfarin Bioequivalence , 2017, CPT: pharmacometrics & systems pharmacology.

[33]  R Lionberger,et al.  Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop , 2017, CPT: pharmacometrics & systems pharmacology.

[34]  Anna Eidelman,et al.  Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets. , 2016, Molecular pharmaceutics.

[35]  A. Babiskin,et al.  Application of Physiologically Based Absorption Modeling for Amphetamine Salts Drug Products in Generic Drug Evaluation. , 2015, Journal of pharmaceutical sciences.

[36]  G. Amidon,et al.  In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  F. Kesisoglou,et al.  Application of Absorption Modeling to Predict Bioequivalence Outcome of Two Batches of Etoricoxib Tablets , 2015, AAPS PharmSciTech.

[38]  Shaofei Xie,et al.  DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles , 2010, The AAPS Journal.

[39]  S. Yamashita,et al.  Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction from a Miniscale Dissolution Test and a Physiologically-Based Computer Simulation , 2008, Pharmaceutical Research.

[40]  Kiyohiko Sugano,et al.  Theoretical dissolution model of poly-disperse drug particles in biorelevant media. , 2008, Journal of pharmaceutical sciences.

[41]  K. Kosmidis,et al.  On the use of the Weibull function for the discernment of drug release mechanisms. , 2006, International journal of pharmaceutics.

[42]  A. Dokoumetzidis,et al.  Analysis of Dissolution Data Using Modified Versions of Noyes–Whitney Equation and the Weibull Function , 2006, Pharmaceutical Research.

[43]  C. Matthews,et al.  Single‐ and Multiple‐Dose Pharmacokinetics of Etoricoxib, a Selective Inhibitor of Cyclooxygenase‐2, in Man , 2003, Journal of clinical pharmacology.

[44]  Michael Levin,et al.  Extended Release Oral Dosage Forms‚ÄîDevelopment,Evaluation, and Application of In Vitro/In Vivo Correlations , 2001 .

[45]  D. Flanagan,et al.  General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. , 1999, Journal of pharmaceutical sciences.

[46]  J. W. Moore,et al.  Mathematical comparison of dissolution profiles , 1996 .

[47]  F Langenbucher,et al.  Letters to the Editor: Linearization of dissolution rate curves by the Weibull distribution , 1972, The Journal of pharmacy and pharmacology.

[48]  A. Noyes,et al.  The rate of solution of solid substances in their own solutions , 1897 .